WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 328057
Description: Capravirine, also known as AG-1549; AG 549; S-1153, is a non-nucleoside reverse transcriptase inhibitor potentially for the treatment of HIV infection.
MedKoo Cat#: 328057
Chemical Formula: C20H20Cl2N4O2S
Exact Mass: 450.0684
Molecular Weight: 451.366
Elemental Analysis: C, 53.22; H, 4.47; Cl, 15.71; N, 12.41; O, 7.09; S, 7.10
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Capravirine; AG-1549; AG 1549; AG1549; AG 549; AG-549; AG549; S-1153; S 1153; S1153;
IUPAC/Chemical Name: (5-((3,5-dichlorophenyl)thio)-4-isopropyl-1-(pyridin-4-ylmethyl)-1H-imidazol-2-yl)methyl carbamate
InChi Key: YQXCVAGCMNFUMQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H20Cl2N4O2S/c1-12(2)18-19(29-16-8-14(21)7-15(22)9-16)26(10-13-3-5-24-6-4-13)17(25-18)11-28-20(23)27/h3-9,12H,10-11H2,1-2H3,(H2,23,27)
SMILES Code: CC(C1=C(SC2=CC(Cl)=CC(Cl)=C2)N(CC3=CC=NC=C3)C(COC(N)=O)=N1)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 451.366 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Li X, Zhan P, De Clercq E, Liu X. The HIV-1 non-nucleoside reverse transcriptase inhibitors (part V): capravirine and its analogues. Curr Med Chem. 2012;19(36):6138-49. Review. PubMed PMID: 22934811.
2: Bu HZ, Zhao P, Kang P, Pool WF, Wu EY, Shetty BV. Evaluation of capravirine as a CYP3A probe substrate: in vitro and in vivo metabolism of capravirine in rats and dogs. Drug Metab Dispos. 2007 Sep;35(9):1593-602. PubMed PMID: 17567732.
3: Bu HZ, Pool WF, Wu EY, Shetty BV. A unique example of drug metabolism: tetra- and penta-oxygenation reactions of capravirine in rats, dogs and humans. Drug Metab Lett. 2007 Jan;1(1):61-5. PubMed PMID: 19356020.
4: Bu HZ, Zhao P, Kang P, Pool WF, Wu EY. Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos. 2006 Nov;34(11):1798-802. PubMed PMID: 16914510.
5: Sato A, Hammond J, Alexander TN, Graham JP, Binford S, Sugita K, Sugimoto H, Fujiwara T, Patick AK. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 2006 Jun;70(2):66-74. PubMed PMID: 16472877.
6: Bu HZ, Kang P, Zhao P, Pool WF, Wu EY. A simple sequential incubation method for deconvoluting the complicated sequential metabolism of capravirine in humans. Drug Metab Dispos. 2005 Oct;33(10):1438-45. PubMed PMID: 16006566.
7: Loksha YM, el-Barbary AA, el-Badawi MA, Nielsen C, Pedersen EB. Synthesis of 2-(aminocarbonylmethylthio)-1H-imidazoles as novel Capravirine analogues. Bioorg Med Chem. 2005 Jul 1;13(13):4209-20. PubMed PMID: 15896963.
8: Gewurz BE, Jacobs M, Proper JA, Dahl TA, Fujiwara T, Dezube BJ. Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study. J Infect Dis. 2004 Dec 1;190(11):1957-61. PubMed PMID: 15529260.
9: Bu HZ, Pool WF, Wu EY, Raber SR, Amantea MA, Shetty BV. Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos. 2004 Jul;32(7):689-98. PubMed PMID: 15205383.
10: Capravirine trials stopped. AIDS Patient Care STDS. 2001 Apr;15(4):225. PubMed PMID: 11359665.